Fierce Biotech Mix Logo.png Fierce Biotech Mix Logo.png
Webinar

From First Patients to Commercial Scale: A CAR-T Therapy Playbook for Autoimmune Disease

ET
60 Minutes

As CAR-T therapies expand into autoimmune diseases, developers face a fundamental challenge: how to deliver personalized treatments safely, reliably, affordably and at a scale capable of supporting thousands of patients. 

Join us for this real-world look at the transition from clinical manufacturing to commercial readiness. We'll discuss translational findings from patients treated with investigational rese-cel manufactured on Cellares' automated Cell Shuttle® platform, including product safety, consistency and early clinical experience. We'll also examine how automation is changing the economics and scalability of CAR-T manufacturing. 

Drawing on their experiences, our experts will explore technology transfer, regulatory comparability, manufacturing reliability, capacity expansion and strategies for manufacturing thousands of patient doses annually. 

You'll leave with practical insights into building a manufacturing strategy that evolves from clinical development to commercial supply. Register today!

Speakers

Gwendolyn Binder

Gwendolyn Binder, PhD

Dr. Binder brings more than 20 years of experience in engineered T cell therapy, from early translational work to commercial-scale manufacturing strategy. She joined Cabaletta Bio in 2019 as one of its first employees, built its research, manufacturing, and quality functions, and now leads research and manufacturing strategy for the company’s cell therapies for autoimmune disease. Previously, she served as Chief Technology Officer at Adaptimmune, where she built out the manufacturing team through the opening of the company’s onsite cell manufacturing facility. At the University of Pennsylvania, she designed and wrote five IND submissions, including for CD19-CAR. She will join the Board of Directors of the Alliance for Regenerative Medicine in January 2027.

0

Ossama Eissa

Mr. Eissa brings more than 20 years of experience in pharmaceutical and biotech manufacturing, including as site head responsible for commercial-scale production of two FDA-approved CAR-T cell therapies. He previously served as Vice President and General Manager at Legend Biotech, leading the Raritan, New Jersey site through the global commercial launch of Carvykti®. At Novartis, he oversaw U.S. manufacturing operations and supported the approval and commercial scale-up of Kymriah®, and at Lonza, he managed Global Strategic Projects in the Cell and Gene Technologies business unit.

Register here!

Date/Time:
ET